tbuckley/cabot-search huggingface dataset:
A phase I study of erlotinib, bevacizumab and gemcitabine in patients with advanced pancreatic cancer
Authors: C. Gomez-Martin, J. C. Camara, H. Cortes, C. Jara, C. Gravalos, B. Rubio, M. L. Amador, M. Hidalgo
Journal: Journal of Clinical Oncology (2007)

4611 Background: Erlotinib is an EGFR TKI active in combination with gemcitabine in p with advanced pancreatic cancer (PC). The combination of gemcitabine and bevacizumab is also active in PC. A phase I of gemcitabine, bevacizumab and erlotinib in p with unresectable locally advanced or metastatic PC is being conducted. Methods: Two cohorts of 6 patients with advanced PC have been treated either with erlotinib (150 mg/day po), bevacizumab (5 mg/Kg iv, days 1 and 15, every 28 days), and either 10 mg/m 2 /min infusion of gemcitabine 850 mg/m 2 or 1,000 mg/m 2 days 1 and 15 every 28 days. P received a maximum of 6 cycles of 28 days. Cohort 1: Daily erlotinib 150 mg po + bevacizumab 5 mg/kg iv days 1 and 15 + gemcitabine 850 mg/m 2 over 10 mg/m 2 /min infusion days 1 and 15. Cohort 2: daily erlotinib 150 mg po + bevacizumab 5 mg/kg iv days 1 and 15 + gemcitabine 100 mg/m 2 over 10 mg/m 2 /min infusion days 1 and 15. Results: 12 p have been included in this study (6 cohort 1 and 6 cohort 2), being evaluable for toxicity. 11 p have concluded the study and 7 have received complete treatment as per protocol. Median age 62.6 yrs (range 38–71); male/female: 5/7 (42%/58%); stage III/IV: 3/9 (25%/75%); Karnofsky index 100%/80%: 2/10. 3 of 6 p in cohort 1 developed gr. 3 asthenia (50%), 2 p gr. 3 neutropenia (33.3%), whereas 1 p had grade 3 leucopenia and gr. 3 skin rash. In cohort 2, most severe adverse events were: 1 case of grade 4 GGT elevation, 1 p gr. 3 skin rash and 1 p. experienced asthenia gr. 3. No severe hematological toxicity in cohort 2 was reported. One p of each cohort required dose reduction of erlotinib, both due to skin rash. Mild diarrhea was reported in 11 of 12 p evaluated. No dose limiting toxicities has been reported. All p were available for response: 2 p reached partial response (both included in cohort 1) and 7 showed stabilization (3 and 4 in cohorts 1 and 2, respectively). No complete responses were observed. Overall disease control index was 75%. Conclusions: The combination of gemcitabine, erlotinib and bevacizumab is well tolerated. MTD has not been reached. Encouraging clinical activity in advanced pancreatic cancer has been observed. Phase I is still ongoing. Toxicity data for all the p will be presented. No significant financial relationships to disclose.
Epigenetic Aging: More Than Just a Clock When It Comes to Cancer
Authors: Ming Yu, William D. Hazelton, Georg E. Luebeck, William M. Grady
Journal: Cancer Research (2019)

The incidence of cancer, adjusted for secular trends, is directly related to age, and advanced chronologic age is one of the most significant risk factors for cancer. Organismal aging is associated with changes at the molecular, cellular, and tissue levels and is affected by both genetic and environmental factors. The specific mechanisms through which these age-associated molecular changes contribute to the increased risk of aging-related disease, such as cancer, are incompletely understood. DNA methylation, a prominent epigenetic mark, also changes over a lifetime as part of an "epigenetic aging" process. Here, we give an update and review of epigenetic aging, in particular, the phenomena of epigenetic drift and epigenetic clock, with regard to its implication in cancer etiology. We discuss the discovery of the DNA methylation-based biomarkers for biological tissue age and the construction of various epigenetic age estimators for human clinical outcomes and health/life span. Recent studies in various types of cancer point to the significance of epigenetic aging in tumorigenesis and its potential use for cancer risk prediction. Future studies are needed to assess the potential clinical impact of strategies focused on lowering cancer risk by preventing premature aging or promoting healthy aging.
AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia
Authors: Greta De Jong, Sophie E Levie, Remko Schotte, Wouter Pos, Daniel Go, Etsuko Yasuda, Madalina Cercel, Susan E van Hal-van Veen, Esmay Frankin, Anikó Szabó, Julien Villaudy, Pauline M van Helden, Hans van Eenennaam, Hergen Spits, Anita W Rijneveld, Mette D Hazenberg
Journal: Blood (2019)
Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer
Authors: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, Andrea Necchi, Pernelle Lavaud, Rafael Morales-Barrera, Teresa Alonso Gordoa, Pablo Maroto, Alain Ravaud, Ignacio Durán, Bernadett Szabados, Daniel Castellano, Patrizia Giannatempo, Yohann Loriot, Joan Carles, Georgia Anguera Palacios, Felix Lefort, Daniele Raggi, Marine Gross Goupil, Thomas Powles, Michiel S. Van der Heijden
Journal: European Urology (2019)
A Novel Population of Oct-4+ SSEA-1+ CXCR4+ CD34+ CD133+ Lin− CD45− Very Small Embryonic-Like (VSEL) Stem Cells Identified in Human Cord Blood.
Authors: Magda Kucia, Maciej Halasa, Marcin Wysoczynski, Magda Baskiewicz-Masiuk, Ewa Zuba-Surma, Bogdan Machalinski, Mariusz Z. Ratajczak
Journal: Blood (2006)
Comprehensive Analysis of Immunophenotype and Transcriptome in Indian T-Acute Lymphoblastic Leukemia - a Prospective Study
Authors: Anita Chopra, Deepak Verma, Shruti Kapoor, Jay Singh, Jayanth Kumar Kumar Palanichamy, Raja Pramanik, Atul Sharma, Sameer Bakhshi, Ranjit Kumar Sahoo, Vinod Scaria, Lalit Kumar, Sridhar Sivasubbu, Rajive Kumar
Journal: Blood (2019)
Complementary Transplantation Improved Results of Both Peripheral Blood Stem Cells and Unrelated Cord Blood Transplants in Thalassemia: A Multi-Center Study from China
Authors: Chunfu Li, Sixi Liu, Yuelin He, Xiaodong Wang, Jianyun Liao, Shan Li, Xiaolin Zheng, Xuedong Wu, Changgang Li, Xiaoqin Feng, Feiqiu Wen, Huaying Liu, Xiaohui Zhou, Zhiyong Peng, Lan He, Chaoke Bu, Leung Wing
Journal: Blood (2019)
Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials
Authors: Katia B Pagnano, Fernanda S Seguro, Eliana C Miranda, Ana Beatriz Pascoal Lopes, Andre Abdo, Marcia Torresan Delamain, Thales Pereira, Gislaine Borba Duarte, Fernanda Maria Santos, Jessica CN Vianna, Matheus Sebastian Da Silva, Luciana Nardinelli, Valquiria Povoa, Graziele Pavan, Bruna R Vergilio, Vanderson Rocha, Carmino Antonio Souza, Erich V De Paula, Israel Bendit
Journal: Blood (2019)
On a Long Way to the Treatment Free Remisson: The Results of the Long-Term Observation of the Chronic Myeloid Leukemia Patients in Russian Part of EUTOS Population-Based Study
Authors: Olga V. Lazareva, Ekaterina Yu. Chelysheva, Anton Kulikovsky, Olga Senderova, Valentina Pepeliaeva, Sergey Meresiy, Alexander S. Luchinin, Galina Milutina, Lubov Gavrilova, Ludmila Avdeeva, Dolgorzhap Dasheeva, Olga Vinogradova, Sergei M. Kulikov, Anna G. Turkina
Journal: Blood (2019)
Amiphenazole and Bronchitis
Authors: J. G. Scadding
Journal: BMJ (1963)

drugs.However, although it is not pos- sible to prove this the responsibility of fluothane for the jaundice seems convincing.While many drugs have been indic- ted as causes of liver damage, this patient received no other agent even suspected of hepato-toxicity.Intra-abdominal opera- tion near the liver and antibiotics have also been blamed; however, this lady was in hospital for immediate and delayed suture of her ulnar nerve, and antibiotics were not administered later than seven weeks before the onset of jaundice.
Unproven Methods of Cancer Treatment: Hubbard E-Meter and Hubbard Electrometer
Authors: L R Hubbard
Journal: CA A Cancer Journal for Clinicians (1966)

The following statement concerning the Hubbard E-Meter and Hubbard Electrometer, pro posed by L. Ron Hubbard, Founder, Academy of Scientology, for the treatment of many diseases and conditions, including cancer, was recently distributed to the 58 Divisions of the Ames-jean Cancer Society for their information.Hubbard E-Meter and Hubbard Electrometer After careful study of the literature and other information available to it, the Ameri can Cancer Society has found no evidence that treatment with the Hubbard E-Meter and Hubbard Electrometer results in any objec tive benefit in the treatment of cancer in human beings.
CD4+ Memory Stem T Cells Recognizing Citrullinated Epitopes Are Expanded in Patients With Rheumatoid Arthritis and Sensitive to Tumor Necrosis Factor Blockade
Authors: Beatrice C. Cianciotti, Eliana Ruggiero, Corrado Campochiaro, Giacomo Oliveira, Zulma I. Magnani, Mattia Baldini, Matteo Doglio, Michela Tassara, Angelo A. Manfredi, Elena Baldissera, Fabio Ciceri, Nicoletta Cieri, Chiara Bonini
Journal: Arthritis & Rheumatology (2019)

Objective Memory stem T (Tscm) cells are long‐lived, self‐renewing T cells that play a relevant role in immunologic memory. This study was undertaken to investigate whether Tscm cells accumulate in rheumatoid arthritis ( RA ). Methods The polarization and differentiation profiles of circulating T cells were assessed by flow cytometry. Antigen‐specific T cells were characterized by staining with major histocompatibility complex class II tetramers. The T cell receptor ( TCR ) repertoire was analyzed by high‐throughput sequencing using an unbiased RNA ‐based approach in CD 4+ T cell subpopulations sorted by fluorescence‐activated cell sorting. Results We analyzed the dynamics of circulating Tscm cells (identified as CD 45 RA + CD 62L+ CD 95+ T cells) by flow cytometry in 27 RA patients, 16 of whom were also studied during treatment with the anti–tumor necrosis factor (anti‐ TNF ) agent etanercept. Age‐matched healthy donors were used as controls. CD 4+ Tscm cells were selectively and significantly expanded in RA patients in terms of frequency and absolute numbers, and significantly contracted upon anti‐ TNF treatment. Expanded CD 4+ Tscm cells displayed a prevalent Th17 phenotype and a skewed TCR repertoire in RA patients, with the 10 most abundant clones representing up to 53.7% of the detected sequences. CD 4+ lymphocytes specific for a citrullinated vimentin (Cit‐vimentin) epitope were expanded in RA patients with active disease. Tscm cells accounted for a large fraction of Cit‐vimentin–specific CD 4+ cells. Conclusion Our results indicate that Tscm cells, including expanded clones specific for relevant autoantigens, accumulate in RA patients not exposed to biologic agents, and might be involved in the natural history of the disease. Further analysis of Tscm cell dynamics in autoimmune disorders may have implications for the design and efficacy assessment of innovative therapies.
Annals Story Slam - Caring
Authors: Andreas Laupacis
Journal: Annals of Internal Medicine (2019)

Web Exclusives5 November 2019Annals Story Slam - CaringFREEAndreas Laupacis, MDAndreas Laupacis, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W19-0021 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Caring "Caring," by Andreas Laupacis, MD (Duration 5:11)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 5 November 2019Volume 171, Issue 9Page: SS1 ePublished: 5 November 2019 Issue Published: 5 November 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.Loading ...
Safety and feasibility of outpatient TPX regimen.
Authors: Dinesh Pendharkar, Hilal Ahmad
Journal: Journal of Clinical Oncology (2012)

e16057 Background: TPF has emerged as standard induction regimen in head and neck cancers. Along with docetaxel and platinum it involves continuous infusion of 5FU, which requires a prolonged admission or use of infusional devices, with added cost of treatment, not practical in many clinical situations and situations with limited resources. Keeping this in view, to make the schedule cost effective and outpatient based, we attempted to replace 5FU with oral capecitabine and study the safety and feasibility of TPX regimen (docetaxel, carboplatin and capecitabine) in advanced cancer patients. Methods: 12 patients (8 male, 4 female, age 51-67, median 58) with advanced metastatic disease, where palliative TPF regimen is generally used ,were prospectively planned to receive fixed dose combination of TPX regimen- docetaxel 120 mg day 1, carboplatin 450 mg day 2 and tab capecitabine 2000mg per day, in two divided doses, for five days q 3 weeks. There were 2 cases of cervical cancer, 3- GI tract and rest 7 had head and neck cancer. They were analysed for toxicity and tolerability. Results: In all 12 patients were given 39 courses of TPX regimen. The toxicities included weakness in 2/39 courses, loss of appetite 2/39, neutropenia grade 1 in 3/39, grade 2 in 3/39. During two course grade 3 neutropenia requiring intervention was recorded. The mucositis grade 1-2 was seen only on two occasions in previously radiated patients. There was no incidence of diarrhea. The treatment was well tolerated. All courses were given on time, and there were no treatment delays related to toxicity. Conclusions: TPX appears to be safe and feasible outpatient alternative to TPF. It has no infusional component allowing it to be used in day care setting. Efficacy data in bigger cohort is warranted.
Mim8 - a Next-Generation FVIII Mimetic Bi-Specific Antibody - Potently Restores the Hemostatic Capacity in Hemophilia a Settings in Vitro and In Vivo
Authors: Stine L Kjellev, Henrik Østergaard, Per Jr Greisen, Mette B Hermit, Karina Thorn, Bjarne G Hansen, Rong Zhou, Jais Rose Bjelke, Marianne Kjalke, Jacob Lund, Thomas L Holm, Carsten Dan Ley, Daniel Elenius, Peter Thygesen, Mette Loftager, Morten G Rasch, Nikolai Lorenzen, Prafull S Gandhi, Kasper Lamberth, Thomas Egebjerg, Søren Lund, Anette Henriksen, Henrik Rahbek-Nielsen, Zhiru Yang, Ida Hilden
Journal: Blood (2019)
Allogeneic Stem Cell Transplantation Has Limited Benefit in Older Patients with Mixed Phenotype Acute Leukemia
Authors: Claire Andrews, Eshetu G Atenafu, Tracy Murphy, Zeyad Al-Shaibani, Steven M Chan, Vikas Gupta, Dennis Dong Hwan Kim, Rajat Kumar, Wilson Lam, Jeffrey H. Lipton, Jonas Mattsson, Dawn Maze, Fotios Michelis, Caroline J McNamara, Aaron D Schimmer, Andre C. Schuh, Hassan Sibai, Auro Viswabandya, Karen W.L. Yee, Mark D. Minden, Arjun Law
Journal: Blood (2019)
Subtyping Diffuse Large B-Cell Lymphoma with Cell-of-Origin Using 32-Gene Expression Assay in Formalin-Fixed Paraffin-Embedded Tissue
Authors: Xiangnan Jiang, Wanhui Yan, Yifeng Sun, Qinghua Xu, Xiaoyan Zhou, Junning Cao, Xiaonan Hong, Xiaoqiu Li
Journal: Blood (2019)
A Novel Short Latency, High Penetrance Model of KRAS Mutation-Driven T-Cell Acute Lymphoblastic Leukemia
Authors: Jacob J. Junco, Vincent Ulysses Gant, Maci S. Terrell, Matthew Benjamin Miller, Chun Shik Park, Taylor J Chen, H. Daniel Lacorazza, Margaret Goodell, Rachel E. Rau, Karen R. Rabin
Journal: Blood (2019)
Spred1 Insufficiency in the Hematopoietic and/or Vascular Compartments of the Bone Marrow (BM) Niche Promotes Aggressive Leukemogenesis in Chronic Myelogenous Leukemia (CML)
Authors: Junjing Qiao, Dandan Zhao, Le Xuan Truong Nguyen, Herman Wu, Gang Liu, Shanshan Suo, Huafeng Wang, Yasmin Elhajmoussa, Chen Liang, David Snyder, Haris Ali, Steven Rosen, Nadia Carlesso, Ling Li, Ya-Huei Kuo, Guido Marcucci, Bin Zhang
Journal: Blood (2019)
Extensive Metabolic Correction of Hurler Disease By Hematopoietic Stem Cell-Based Gene Therapy: Preliminary Results from a Phase I/II Trial
Authors: Bernhard Gentner, Maria Ester Bernardo, Francesca Tucci, Erika Zonari, Francesca Fumagalli, Silvia Pontesilli, Serena Acquati, Paolo Silvani, Fabio Ciceri, Attilio Rovelli, Giancarlo La Marca, Rossella Parini, Silvia Gregori, Eugenio Montini, Luigi Naldini, Alessandro Aiuti
Journal: Blood (2019)
PDTM-32. RESOLVING MEDULLOBLASTOMA CELLULAR ARCHITECTURE BY SINGLE-CELL GENOMICS
Authors: Laure Bihannic, Volker Hovestadt, Kyle Smith, Mariella Filbin, McKenzie Shaw, Alicia Baumgartner, John DeWitt, Andrew Groves, Lisa Mayr, Hannah Weisman, Alyssa Richman, Marni Shore, Liliana Goumnerova, Celeste Rosencrance, Robert Carter, Timothy Phoenix, Jennifer Hadley, Yiai Tong, Jim Houston, Richard Ashmun, Michael DeCuypere, Tanvi Sharma, Keith Ligon, Scott Pomeroy, Miguel Rivera, Orit Rozenblatt-Rosen, Jessica Rusert, Robert Wechsler-Reya, Xiao-Nan Li, Andreas Peyrl, Johannes Gojo, Dominik Kirchhofer, Daniela Lötsch, Thomas Czech, Christian Dorfer, Christine Haberler, Rene Geyeregger, Angela Halfmann, Charles Gawad, John Easton, Stefan Pfister, Aviv Regev, Amar Gajjar, Brent Orr, Irene Slavc, Giles Robinson, Bradley Bernstein, Mario Suvà, Paul Northcott
Journal: Neuro-Oncology (2019)

Abstract Medulloblastoma is a malignant childhood cerebellar tumor comprised of distinct molecular subgroups. Whereas genomic characteristics of these subgroups are well defined, the extent to which cellular diversity underlies their divergent biology and clinical behaviour remains largely unexplored. We used single-cell transcriptomics to investigate intra- and inter-tumoral heterogeneity in twenty-five medulloblastomas spanning all molecular subgroups. WNT, SHH, and Group 3 tumors comprised subgroup-specific undifferentiated and differentiated neuronal-like malignant populations, whereas Group 4 tumors were exclusively comprised of differentiated neuronal-like neoplastic cells. SHH tumors closely resembled granule neurons of varying differentiation states that correlated with patient age. Group 3 and Group 4 tumors exhibited a developmental trajectory from primitive progenitor-like to more mature neuronal-like cells, whose relative proportions distinguished these subgroups. Cross-species transcriptomics defined distinct glutamatergic populations as putative cells-of-origin for SHH and Group 4 subtypes. Collectively, these data provide novel insights into the cellular and developmental states underlying subtype-specific medulloblastoma biology.
Utilizing Multiple Linked Populations Registers to Estimate Incidence and Prevalence of Multiple Myeloma in Sweden and Denmark from the Real-World HUMANS Study
Authors: Markus Hansson, Niels Abildgaard, Anders Waage, Pekka Anttila, Anders Green, Katrine Hass Rubin, Lill-Brith von Arx, Mate Szilcz, Yuanjun Ma, Sigurd Ørstavik, Nawal Bent-Ennakhil, Jonatan Freilich, François Gavini
Journal: Blood (2019)
Changes in N-Glycosylation Induced By Somatic Hypermutation Modulate the Antigen Reactivity of the Immunoglobulin Receptors in CLL Stereotyped Subset #201
Authors: Maria Gounari, Anastasia Iatrou, Kostantia Kotta, Ioannis Sarrigeorgiou, Peggy Lymberi, Anastasia Chatzidimitriou, Kostas Stamatopoulos
Journal: Blood (2019)
Health Care for All Must Include Everyone
Authors: Jonathan B. Miller, Elora Mukherjee
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Increased Libiodo with Chlorprothixene
Authors: G. Sedman
Journal: BMJ (1963)

with the tissue-buffering mechanism for storage of catechol amines.Under these circumstances it is also likely that the tissue monoamine system is more sensi- tive to the action of ephedrine and amphetamine.It is clear that tranylcypromine should never be given either in the form of " parstelin " (tranylcypromine and trifluo- perazine) or of " parnate " (tranylcypromine) within one to two weeks of giving ephedrine or amphetamine as well.In view of the pharmacological action of the drug on so many systems it should probably not be given with anything else at all, at any rate in the present state of our knowledge.The side-effects of tranylcypromine are due to amine-oxidase inhibition, but there is comparatively little to suggest that this is true of its antidepressant action.One hopes that it will be possible to separate these effects.since the practical difficulty of ensuring that a patient will not con- sume other tablets as well as tranylcypromine makes the drug a liability in prac- tice.Although all these effects have been known since 1960 they are often still unrecognized.-Iam, etc.,
Multicentre, Open Label, Randomized Phase III Study of Cpi-613® (devimistat) in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (≥ 60 years) with Relapsed / Refractory Acute Myeloid Leukemia (AML) - Armada 2000 (AML003) Trial
Authors: Timothy S. Pardee, Sanjeev Luther, Marc E. Buyse, Bayard L Powell, Jorge E. Cortes
Journal: Blood (2019)
Fertility Rates in Young Hodgkin Lymphoma Survivors: A Danish Nationwide Cohort Study of 769 Patients
Authors: Andreas Kiesbye Øvlisen, Lasse H. Jakobsen, Kristian Hay Kragholm, Martin Hutchings, Henrik Frederiksen, Peter Kamper, Sandra Eloranta, Caroline Weibull, Ingrid Glimelius, Karin Ekstrom Ekstroem Smedby, Marianne Tang Severinsen, Tarec Christoffer C. El-Galaly
Journal: Blood (2019)
Prevalence and Effects of Polypharmacy on Overall Survival (OS) of Acute Myeloid Leukemia (AML)
Authors: Prajwal Dhakal, Elizabeth R. Lyden, Kate-Lynn E Muir, Zaid S. Al-Kadhimi, Thuy T. Koll, Lori J. Maness, Krishna Gundabolu, Vijaya R. Bhatt
Journal: Blood (2019)
Accumulation of DNA Damage and Alteration of the DNA Damage Response in Chronic Myeloid Leukemia
Authors: Henning D. Popp, Vanessa Kohl, Johanna Flach, Susanne Brendel, Helga Kleiner, Wolfgang Seifarth, Christel Weiss, Susanne Saussele, Wolf-Karsten Hofmann, Alice Fabarius
Journal: Blood (2019)
Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Authors: Norman J. Lacayo, Vinod A. Pullarkat, Wendy Stock, Elias Jabbour, Ashish Bajel, Jeffrey Rubnitz, Jessica Leonard, Charles G. Mullighan, Seong Lin Khaw, Susan I. Vear, Joseph T. Opferman, Ahmed Hamed Salem, Michelle Schmidt, Bo Tong, Lang Zhou, Jeremy A. Ross, Lindsey Bensman, Amanda Jacobson, Robin Norris, Thomas Alexander
Journal: Blood (2019)